- Report
- September 2026
- 198 Pages
Global
From €3274EUR$3,545USD£2,739GBP
€3638EUR$3,939USD£3,043GBP
- Report
- September 2026
- 189 Pages
Global
From €3274EUR$3,545USD£2,739GBP
€3638EUR$3,939USD£3,043GBP
- Report
- September 2026
- 189 Pages
Global
From €3274EUR$3,545USD£2,739GBP
€3638EUR$3,939USD£3,043GBP
- Report
- September 2026
- 185 Pages
Global
From €3274EUR$3,545USD£2,739GBP
€3638EUR$3,939USD£3,043GBP
- Report
- September 2026
- 194 Pages
Global
From €3274EUR$3,545USD£2,739GBP
€3638EUR$3,939USD£3,043GBP
- Report
- September 2026
- 185 Pages
Global
From €3274EUR$3,545USD£2,739GBP
€3638EUR$3,939USD£3,043GBP
- Report
- January 2026
- 193 Pages
Global
From €3274EUR$3,545USD£2,739GBP
€3638EUR$3,939USD£3,043GBP
- Report
- January 2026
- 195 Pages
Global
From €3274EUR$3,545USD£2,739GBP
€3638EUR$3,939USD£3,043GBP
- Report
- November 2025
- 183 Pages
Global
From €4156EUR$4,500USD£3,476GBP
- Report
- October 2026
- 419 Pages
Global
From €5403EUR$5,850USD£4,519GBP
- Report
- October 2026
- 590 Pages
Global
From €5403EUR$5,850USD£4,519GBP
- Report
- October 2026
- 367 Pages
Global
From €5403EUR$5,850USD£4,519GBP
- Report
- October 2026
- 180 Pages
Global
From €5403EUR$5,850USD£4,519GBP
- Report
- October 2026
- 282 Pages
Global
From €5403EUR$5,850USD£4,519GBP
- Report
- October 2026
- 233 Pages
Global
From €5403EUR$5,850USD£4,519GBP
- Report
- October 2026
- 181 Pages
Global
From €5403EUR$5,850USD£4,519GBP
- Report
- October 2026
- 246 Pages
Global
From €5403EUR$5,850USD£4,519GBP
- Report
- October 2026
- 377 Pages
Global
From €5403EUR$5,850USD£4,519GBP
- Report
- October 2026
- 466 Pages
Global
From €5403EUR$5,850USD£4,519GBP
- Report
- October 2026
- 84 Pages
Global
From €5403EUR$5,850USD£4,519GBP

CAR T Cell therapy is a type of immunotherapy used to treat certain types of cancer. It is a type of gene therapy that uses a patient's own immune cells to recognize and attack cancer cells. The patient's T cells are collected and modified to express a chimeric antigen receptor (CAR) that binds to a specific antigen on the surface of the cancer cells. The modified T cells are then infused back into the patient, where they can recognize and attack the cancer cells.
CAR T Cell therapy has been approved for the treatment of certain types of blood cancers, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). It is also being studied for the treatment of other types of cancer, including solid tumors.
CAR T Cell therapy is a rapidly growing field, with many companies developing and marketing products. Some of the major players in the market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Cellectis. Show Less Read more